Please login to the form below
niraparib
This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.
GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
GSK gained dostarlimab from its $5.1bn acquisition of cancer specialist Tesaro, as well as PARP inhibitor Zejula (niraparib), which is approved across a number of indications including ovarian, fallopian tube
Latest news
-
EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer
That includes GlaxoSmithKline’s (GSK) Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib).
-
FDA accepts review to broaden GSK’s Zejula label
GSK is seeking approval for Zejula (niraparib) as a first-line maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of biomarker status.
-
GSK pays $50m upfront to tap Immatics’ cell therapy platform
GSK took full ownership of the therapy in 2018. GSK’s push into cancer has also included its $5.1bn acquisition of Tesaro, which brought in PARP inhibitor Zejula (niraparib).
-
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
The filing means that Rubraca has beaten rivals such as AstraZeneca/Merck &Co’s market-leading Lynparza (olaparib), GlaxoSmithKline/Janssen’s Zejula (niraparib) and Pfizer’s new entrant Talzenna (talazoparib) to
-
FDA starts speedy review of Lynparza plus Avastin in ovarian cancer
If the FDA backs the new indication it will help AZ and Merck to maintain their lead over newer rivals in the PARP inhibitor class, including GlaxoSmithKline’s Zejula (niraparib), Clovis
EU gives AZ’s Lynparza green light for BRCA-mutated pancreatic cancer
FDA accepts review to broaden GSK’s Zejula label
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
FDA starts speedy review of Lynparza plus Avastin in ovarian cancer
More from news
Approximately 4 fully matching, plus 41 partially matching documents found.
Latest Intelligence
-
Deal Watch April 2016
Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP
Deal Watch April 2016
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
- Cuttsy+Cuttsy awarded Gold accreditation by Investors in People
- Nudging someone in the right direction isn’t always easy – that’s where behavioural science comes in
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars
- Lucid Group celebrates a double win at Communiqué 2021
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
